Background:
There is limited data on the prevalence of fostemsavir (FTR)-associated drug resistance mutations in people with HIV (PWH) in Botswana. Botswana is currently experiencing increased cases of patients with MDR HIV strains, which may limit future antiretroviral therapy (ART) options. We here use a large set of HIV-1 C sequences from across Botswana to determine the possibility of the use of FTR-containing regimens by exploring the prevalence of FTR-associated resistance mutations among ART-naïve and -experienced individuals in Botswana.
Methods:
Previously reported FTR-associated drug resistance mutations (DRMs) were surveyed from 6,030 HIV-1 near full-length sequences generated from participants of the Botswana Combination Prevention Project (BCPP) (2013-2018). Both antiretroviral (ART)-naïve and experienced were included. ART experienced individuals were further classified into suppressed (VL≤400 copies/mL) and virologic failure ((VF) (VL >400 copies/mL)).
Results:
Among 6,030 HIV-1 gp120 sequences, 1,282 (21.3%) were ART naïve participants while 4748 (78.7%) were on ART at study enrolment. VL data was available for 4,739 (99.8%) among ART experienced, of whom 4526 (95.5%) were suppressed and 213 (4.5%) had VL >400 copies/mL (VF). The overall prevalence of FTR resistance was 13.3% (CI 11.6-15.1). Stratifying the prevalence by ART status, 13.6%(29/213) was reported among ART experienced with VF and 13.3% (170/1282) in ART naïve individuals (p-value=0.9) . The most predominant mutations were M434I and M475I reported among 60.3% and 36.2% individuals, respectively. Mutation M434V was higher at ART experienced ( 10.3%) compared to 1.2% among ART-naïve individuals (p > 0.01).
Conclusions:
The overall prevalence of FTR DRM was similar in ART naïve and ART experienced individuals in a setting with no prior FTR exposure. We recommend periodic surveillance of FTR-associated drug resistance mutations in order to guide its clinical use in people living with HIV.